MMC hires first CMO

The integrated agency's pharmaceutical business now brings in half its billings.

Therapeutic Focus: Oncology

Therapeutic Focus: Oncology

Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment

Headliner: Silk smooths Takeda myeloma shift

Headliner: Silk smooths Takeda myeloma shift

He didn't want to just invest in a winning horse—he wanted to help groom it

The MM&M Weekly News Quiz: July 24

The MM&M Weekly News Quiz: July 24

Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

BMS US sales are down, despite growing Opdivo adoption

BMS US sales are down, despite growing Opdivo adoption

Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.

Physicians Interactive acquires Quantia

Physicians Interactive acquires Quantia

The deal is expected to complement the company's digital health platform.

Five things for pharma marketers to know: Thursday, July 23

Five things for pharma marketers to know: Thursday, July 23

Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition

Editor's Desk: Off-label and on the record

Editor's Desk: Off-label and on the record

Taking a look back at what's happened—and what hasn't happened—on the healthcare communications policy front so far this summer

Leadership Exchange: 21st Century Promotion

Leadership Exchange: 21st Century Promotion

From the 21st Century Cures Act to Amarin's off-label suit, Marc Iskowitz asks seven experts what the confluence of policy developments means for pharma promotion

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.

Praluent's FDA review looms, but questions persist

Praluent's FDA review looms, but questions persist

A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Orchestrating Key Stakeholder Engagement for Launch Success

Orchestrating Key Stakeholder Engagement for Launch Success

The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.

Allergan debuts #ActuallySheCan campaign

Allergan debuts #ActuallySheCan campaign

The new campaign seeks to connect with millennial women.

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

CMS updates CME guidance

CMS updates CME guidance

New rules will require manufacturers to report some indirect payments made to physicians for CME activities.

The FDA seeks comments on DTC ad perception

The agency plans to research extrinsic factors that influence the way a patient perceives a drug.

HRM merges with Spirit Health Group to form Relevate

The agency and community program provider will form a new healthcare marketing company, Relevate Health Group.

Five things for pharma marketers to know: Monday, July 20

Five things for pharma marketers to know: Monday, July 20

Robert Ingram sounds off on drug transparency laws in WSJ op-ed; patients with certain forms of leukemia went into complete remission after taking Amgen's cancer drug; Eli Lilly's future in Alzheimer's disease pinned to new data surfacing this week

Five things for pharma marketers to know: Friday, July 17

Five things for pharma marketers to know: Friday, July 17

Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker

NORD and University of Maryland partner for rare-disease research training

The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.

Patients expect pharma will boost engagement

Patients expect pharma will boost engagement

The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.

Five things for pharma marketers to know: Thursday, July 16

Five things for pharma marketers to know: Thursday, July 16

The FDA discusses working with Google to identify unknown drug side effects; Tavenner named chief of insurer lobby group; drugmakers are starting to use cultural experts to better understand patient experience.

Pricing pressure drives pharma collaborations, report says

Pricing pressure drives pharma collaborations, report says

The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.

New Sanofi CEO reorganizes company

The restructuring is expected to simplify the drugmaker's organization.

Five things for pharma marketers to know: Wednesday, July 15

Five things for pharma marketers to know: Wednesday, July 15

Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands

J&J prepares to defend Remicade market share

J&J prepares to defend Remicade market share

Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.

Private equity firm acquires CME provider

Vesey Street Capital Partners acquired Atlanta-based CME provider Imedex.

Five things for pharma marketers to know: Tuesday, July 14

Five things for pharma marketers to know: Tuesday, July 14

The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices

More than 400 drugs in development for neurological disorders

PhRMA and the Epilepsy Foundation said 50-million Americans are affected by disorders such as Alzheimer's disease and multiple sclerosis.

Five things for pharma marketers to know: Monday, July 13

Five things for pharma marketers to know: Monday, July 13

Harvoni is now prescribed more than Sovaldi; healthcare group says new hepatitis-C drugs are cost-effective; Roche antibody shrank tumors in certain bladder-cancer patients

21st Century Cures, Amarin Court Case Advance

21st Century Cures, Amarin Court Case Advance

Pharma's efforts to evolve restrictions about off-label marketing move forward.

Five things for pharma marketers to know: Friday, July 10

Five things for pharma marketers to know: Friday, July 10

21st Century Cures legislation passes the House; Novartis's heart-failure drug may launch with "beyond the pill" services; Purdue and GSK are working on using Apple's ResearchKit; the FDA issues warning letter on co-pay card

Read the complete July 2015 Digital Edition

Read the complete July 2015 Digital Edition

Click the link below to access the Digital Edition of the July 2015 issue of MM&M, with all text, charts and pictures.

FDA panel says benefits outweigh risks for Lilly's lung-cancer drug

Eli Lilly's lung-cancer antibody, necitumumab, has incremental benefits, according to an FDA advisory panel.

House expected to vote on 21st Century Cures

House expected to vote on 21st Century Cures

The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.

Five things for pharma marketers to know: Thursday, July 9

Five things for pharma marketers to know: Thursday, July 9

Pregnant women taking Prozac or Paxil have higher risks of birth defects; study finds J&J's experimental psoriasis drug works better than Humira; AstraZeneca divests global rights to Entocort

Drug industry's CME support swings to a 2% gain

Drug industry's CME support swings to a 2% gain

Last year's increase in CME support from manufacturers came after six straight years of declining budgets.

AdComm Preview: Eli Lilly's lung-cancer drug

AdComm Preview: Eli Lilly's lung-cancer drug

An FDA advisory panel will discuss the fate of Lilly's investigational lung-cancer antibody, necitumumab, which improved overall survival incrementally but also had one late-stage trial halted due to an "imbalanced number of deaths" attributed to blood clots.

Novartis bets on demand for new heart-failure drug Entresto

Novartis bets on demand for new heart-failure drug Entresto

The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.

MDC Partners hangs out new healthcare shingle

The agency adds health and wellness offerings to the holding company's existing capabilities.

Five things for pharma marketers to know: Wednesday, July 8

Five things for pharma marketers to know: Wednesday, July 8

CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen

Insurance trade group says new HCV drugs could cost California billions

An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.

FDA advisory panelists describe decision to recommend approval of "female Viagra"

FDA advisory panelists describe decision to recommend approval of "female Viagra"

Three panelists from the FDA's advisory panel offered their views on the panel's decision to recommend approval of Sprout Pharmaceuticals' flibanserin

Five things for pharma marketers to know: Tuesday, July 7

Five things for pharma marketers to know: Tuesday, July 7

Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher

Curious if you're a finalist in the MM&M Awards? Find out now

Curious if you're a finalist in the MM&M Awards? Find out now

The finalists in each of the 32 categories for this year's MM&M Awards are revealed here.

Vertex's Orkambi nabs FDA approval but may face payer backlash

Vertex's Orkambi nabs FDA approval but may face payer backlash

The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.

Steady Leadership, Focus on Infrastructure Expected from the FDA's "Acting" Head

Steady Leadership, Focus on Infrastructure Expected from the FDA's "Acting" Head

Dr. Stephen Ostroff took over as the FDA's acting commissioner when Dr. Margaret Hamburg stepped down in March.

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Index of Agencies and Advertisers

Please open the PDF (named Index) below for a complete listing from our July 2015 issue

MM&M's Agency Solar System

MM&M's Agency Solar System

North American healthcare agencies and the holding companies that own them

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Top 100 Agencies 2015: Wunderman Health

Top 100 Agencies 2015: Wunderman Health

Digital accounts for more than happiness

Top 100 Agencies 2015: W2O Group

Top 100 Agencies 2015: W2O Group

An agency with a "no walls" philosophy

Top 100 Agencies 2015: Triple Threat Communications

Top 100 Agencies 2015: Triple Threat Communications

Motivation, ability and trigger

Top 100 Agencies 2015: Trio

Top 100 Agencies 2015: Trio

Keeping up with the times while integrating into a new family

Top 100 Agencies 2015: Topin & Associates, an HCB Health Company

Top 100 Agencies 2015: Topin & Associates, an HCB Health Company

A veteran Chicago shop has a new parent

Top 100 Agencies 2015: Sudler & Hennessey

Top 100 Agencies 2015: Sudler & Hennessey

Offering clients solutions they didn't even know they needed yet

Top 100 Agencies 2015: STRIKEFORCE Communications

Top 100 Agencies 2015: STRIKEFORCE Communications

A smaller agency thinks and acts big

Top 100 Agencies 2015: StoneArch

Top 100 Agencies 2015: StoneArch

Aligning across healthcare's continuum

Top 100 Agencies 2015: Siren Interactive

Top 100 Agencies 2015: Siren Interactive

A surge follows an acquisition

Top 100 Agencies 2015: Scout

Top 100 Agencies 2015: Scout

Independence has its rewards

Top 100 Agencies 2015: Saatchi & Saatchi Wellness

Top 100 Agencies 2015: Saatchi & Saatchi Wellness

A new move promotes new energy

Agency Revenue Rankings

Networks and agencies, ranked by 2014 US revenue

Top 100 Agencies 2015: RevHealth

Top 100 Agencies 2015: RevHealth

An agency with degrees of certainty

Top 100 Agencies 2015: Renavatio Healthcare Communications

Top 100 Agencies 2015: Renavatio Healthcare Communications

Daredevil depth-defying devotion

Top 100 Agencies 2015: Razorfish Health

Top 100 Agencies 2015: Razorfish Health

Real transformation in action

Top 100 Agencies 2015: Purohit Navigation

Top 100 Agencies 2015: Purohit Navigation

Making a specialty of specialty work

Top 100 Agencies 2015: PulseCX

Top 100 Agencies 2015: PulseCX

Searching for transformational change

Top 100 Agencies 2015: Publicis Life Brands Medicus

Top 100 Agencies 2015: Publicis Life Brands Medicus

Transparency: right for clients and staff

Top 100 Agencies 2015: Precision For Value

Top 100 Agencies 2015: Precision For Value

A sharp focus on managed markets

Top 100 Agencies 2015: Palio

Top 100 Agencies 2015: Palio

A rebranded leadership team leads a rebranded agency

Top 100 Agencies 2015: Pacific Communications

Top 100 Agencies 2015: Pacific Communications

Keeping steady amid storms

Top 100 Agencies 2015: Pace

Top 100 Agencies 2015: Pace

Realignment leads to rebranding and success (plus flexibility and growth)

Top 100 Agencies 2015: Ogilvy CommonHealth Worldwide

Top 100 Agencies 2015: Ogilvy CommonHealth Worldwide

An agency running on all cylinders

Top 100 Agencies 2015: Neon

Top 100 Agencies 2015: Neon

A young agency transcends its "conflict shop" lineage

Sermo expands to Canada in global expansion

Sermo expands to Canada in global expansion

The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.

Top 100 Agencies 2015: MicroMass

Top 100 Agencies 2015: MicroMass

Fusing behavioral science with the art of storytelling

Pharmacy groups urge consistent naming of biosimilars

Pharmacy groups urge consistent naming of biosimilars

The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.

Top 100 Agencies 2015: Merkle

Top 100 Agencies 2015: Merkle

Building growth on marketing analytics

Top 100 Agencies 2015: MedThink Communications

Top 100 Agencies 2015: MedThink Communications

A Caroline shop looks to diversify

Top 100 Agencies 2015: MediMedia Managed Markets

Top 100 Agencies 2015: MediMedia Managed Markets

Coming out ahead after an acquisition

Top 100 Agencies 2015: McK|CP Healthcare

Top 100 Agencies 2015: McK|CP Healthcare

A merger that makes sense

Top 100 Agencies 2015: McCann Torre Lazur

Top 100 Agencies 2015: McCann Torre Lazur

A launch agency keeps new-product role

Top 100 Agencies 2015: McCann Regan Campbell Ward

Top 100 Agencies 2015: McCann Regan Campbell Ward

Being part of something bigger is okay

Top 100 Agencies 2015: McCann HumanCare North America

Top 100 Agencies 2015: McCann HumanCare North America

Pushing the envelope to evolve wisely

Top 100 Agencies 2015: McCann Echo

Top 100 Agencies 2015: McCann Echo

Distinguishing itself from its sister firms

Top 100 Agencies 2015: McCann Managed Markets

Top 100 Agencies 2015: McCann Managed Markets

Reaching a tipping point is both exciting and rewarding

Top 100 Agencies 2015: Maricich Healthcare Communication

Top 100 Agencies 2015: Maricich Healthcare Communication

Guileless enthusiasm speaks volumes

Top 100 Agencies 2015: LLNS

Top 100 Agencies 2015: LLNS

A transitional year paved the way for new openings at this venerable agency

Top 100 Agencies 2015: LehmanMillet

Top 100 Agencies 2015: LehmanMillet

Trustworthiness is a business basic for this longtime Boston agency

Top 100 Agencies 2015: Lanmark360

Top 100 Agencies 2015: Lanmark360

Moving beyond dental while steadily pushing into digital

Top 100 Agencies 2015: Klick Health

Top 100 Agencies 2015: Klick Health

Ice cream? Salons? Klick does it all, and does it well

Top 100 Agencies 2015: JUICE Pharma Worldwide

Top 100 Agencies 2015: JUICE Pharma Worldwide

Being one of the best one-stop shops makes growing all the easier

Top 100 Agencies 2015: IOMEDIA

Top 100 Agencies 2015: IOMEDIA

This digital firm has made the fully realized leap from 2-D to 3-D

Agency Intro: Not Your Father's Agency

Agency Intro: Not Your Father's Agency

Agency business again appears to be up for a healthy cross-section of companies this year. And, according to our annual business barometer of healthcare firms, the new agency is thriving on a diet of mostly digital work on both the HCP and consumer sides. Meanwhile, the increased emphasis on creating memorable content and patient-centered user experiences appears to be a driving force in pharmaceutical clients' marketing strategy. Marc Iskowitz reports

Top 100 Agencies 2015: INVIVO Communications

Top 100 Agencies 2015: INVIVO Communications

Focusing on a solid set of core skills

Top 100 Agencies 2015: inVentiv Health Public Relations Group

Top 100 Agencies 2015: inVentiv Health Public Relations Group

A new name but a story long in the making

Top 100 Agencies 2015: Intouch Solutions

Top 100 Agencies 2015: Intouch Solutions

Digital prowess drives this Kansas City-based agency toward the $100-million mark

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.